BCL2 and Thrombocytopenia: For example, treatment with the BCL-2 inhibitor and a senolytic drug ABT-263 causes transient thrombocytopenia [49–51], which may reflect the fact that mature megakaryocytes themselves appear to be physiologically senescent cells [52].